[go: up one dir, main page]

WO2023244511A3 - Improved glycan-dependent chimeric antigen receptor cells - Google Patents

Improved glycan-dependent chimeric antigen receptor cells Download PDF

Info

Publication number
WO2023244511A3
WO2023244511A3 PCT/US2023/024956 US2023024956W WO2023244511A3 WO 2023244511 A3 WO2023244511 A3 WO 2023244511A3 US 2023024956 W US2023024956 W US 2023024956W WO 2023244511 A3 WO2023244511 A3 WO 2023244511A3
Authority
WO
WIPO (PCT)
Prior art keywords
chimeric antigen
glycan
improved
taca
cars
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2023/024956
Other languages
French (fr)
Other versions
WO2023244511A2 (en
Inventor
Michael Demetriou
Raymond Wenhou Zhou
Yanni ZHU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2023292081A priority Critical patent/AU2023292081A1/en
Priority to CA3258445A priority patent/CA3258445A1/en
Priority to IL317580A priority patent/IL317580A/en
Priority to JP2024573283A priority patent/JP2025520384A/en
Priority to KR1020257001020A priority patent/KR20250036972A/en
Priority to EP23824455.2A priority patent/EP4536282A2/en
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Priority to CN202380059379.0A priority patent/CN119698297A/en
Publication of WO2023244511A2 publication Critical patent/WO2023244511A2/en
Publication of WO2023244511A3 publication Critical patent/WO2023244511A3/en
Priority to MX2024015583A priority patent/MX2024015583A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Provided are compositions and methods for treating diseases associated with aberrant glycosylation of cell surface molecules and expression of tumor-associated carbohydrate antigens (TACA). Also provided are chimeric antigen receptors (CARs) specific to tumor-associated carbohydrate antigens (TACA-CARs), vectors encoding the TACA-CARs, and recombinant cells comprising the TACA CARs.
PCT/US2023/024956 2022-06-13 2023-06-09 Improved glycan-dependent chimeric antigen receptor cells Ceased WO2023244511A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA3258445A CA3258445A1 (en) 2022-06-13 2023-06-09 Improved glycan-dependent chimeric antigen receptor cells
IL317580A IL317580A (en) 2022-06-13 2023-06-09 Improved glycan-dependent chimeric antigen receptor cells
JP2024573283A JP2025520384A (en) 2022-06-13 2023-06-09 Improved glycan-dependent chimeric antigen receptor cells
KR1020257001020A KR20250036972A (en) 2022-06-13 2023-06-09 Improved glycan-dependent chimeric antigen receptor cells
EP23824455.2A EP4536282A2 (en) 2022-06-13 2023-06-09 Improved glycan-dependent chimeric antigen receptor cells
AU2023292081A AU2023292081A1 (en) 2022-06-13 2023-06-09 Improved glycan-dependent chimeric antigen receptor cells
CN202380059379.0A CN119698297A (en) 2022-06-13 2023-06-09 Improved glycan-dependent chimeric antigen receptor cells
MX2024015583A MX2024015583A (en) 2022-06-13 2024-12-13 Improved glycan-dependent chimeric antigen receptor cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263351746P 2022-06-13 2022-06-13
US63/351,746 2022-06-13

Publications (2)

Publication Number Publication Date
WO2023244511A2 WO2023244511A2 (en) 2023-12-21
WO2023244511A3 true WO2023244511A3 (en) 2024-02-29

Family

ID=89191814

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/024956 Ceased WO2023244511A2 (en) 2022-06-13 2023-06-09 Improved glycan-dependent chimeric antigen receptor cells

Country Status (9)

Country Link
EP (1) EP4536282A2 (en)
JP (1) JP2025520384A (en)
KR (1) KR20250036972A (en)
CN (1) CN119698297A (en)
AU (1) AU2023292081A1 (en)
CA (1) CA3258445A1 (en)
IL (1) IL317580A (en)
MX (1) MX2024015583A (en)
WO (1) WO2023244511A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025111484A1 (en) * 2023-11-21 2025-05-30 The Board Of Trustees Of The Leland Stanford Junior University Cellular therapies targeting aberrant glycosylation in solid malignancies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190336533A1 (en) * 2016-12-28 2019-11-07 Green Cross Lab Cell Corporation Chimeric antigen receptor and natural killer cells expressing same
US20210032363A1 (en) * 2017-03-31 2021-02-04 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling
US20210113709A1 (en) * 2015-05-01 2021-04-22 The Regents Of The University Of California Glycan-dependent Immunotherapeutic Molecules

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210113709A1 (en) * 2015-05-01 2021-04-22 The Regents Of The University Of California Glycan-dependent Immunotherapeutic Molecules
US20190336533A1 (en) * 2016-12-28 2019-11-07 Green Cross Lab Cell Corporation Chimeric antigen receptor and natural killer cells expressing same
US20210032363A1 (en) * 2017-03-31 2021-02-04 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling

Also Published As

Publication number Publication date
MX2024015583A (en) 2025-04-02
WO2023244511A2 (en) 2023-12-21
KR20250036972A (en) 2025-03-14
AU2023292081A1 (en) 2025-01-09
CN119698297A (en) 2025-03-25
JP2025520384A (en) 2025-07-03
EP4536282A2 (en) 2025-04-16
IL317580A (en) 2025-02-01
CA3258445A1 (en) 2023-12-21

Similar Documents

Publication Publication Date Title
WO2020092854A3 (en) Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d)
AU2024201166A1 (en) Glycan-interacting compounds and methods of use
WO2004029092A3 (en) Antibody for adcc and inducing cytokine production
AR123362A2 (en) MESOPOROUS SILICA PARTICLE COMPOSITIONS FOR VIRAL DELIVERY
JP6951973B2 (en) Glycan interacting compounds and how to use
WO2021260208A3 (en) Sulfated peptides for chemokine receptor antibody generation
WO2023244511A3 (en) Improved glycan-dependent chimeric antigen receptor cells
WO2020232427A3 (en) Therapeutic compositions and methods for treating cancer in combination with analogs of interleukin proteins
WO2022251120A3 (en) Nkg2d-based chimeric antgen receptor
WO2024031091A3 (en) Chimeric antigen receptors specific for gprc5d and bcma
WO2023244499A3 (en) Improved glycan-dependent immunotherapeutic bi-specific fusion proteins and chimeric antigen receptors
WO2024086842A3 (en) Cells and compositions for treating cancer
WO2023244510A3 (en) Improved glycan-dependent immunotherapeutic bi-specific proteins with longer half-life
IL78172A (en) Monoclonal antibodies for use in the isolation and determination of atrial,natriuertic peptides(anp)of mammals
WO2024030583A3 (en) Novel constructs for chimeric antigen receptors and uses thereof
WO2024178397A3 (en) Modified immune effector cells and methods of use
Mark et al. B‐cell lymphoma marking only with anti‐epithelial. Membrane antigen
WO2023215746A9 (en) Anti-alppl2 antibodies and chimeric antigen receptors, and compositions and methods of use
WO2024243325A3 (en) Combination of pac-1 and car t-cell treatments
Shitara et al. Immunoglobulin class switch of anti-ganglioside monoclonal antibody from IgM to IgG
Lin et al. Analysis of a murine anti-ganglioside GD2 monoclonal antibody expressing both IgG2a and IgG3 isotypes: monoclonality, apoptosis triggering, and activation of cellular cytotoxicity on human melanoma cells
Khosravi et al. Structural characterization and biosynthesis of gp87, a melanoma‐associated oncofetal antigen defined by monoclonal antibody 140.240
WO2024107646A8 (en) Anti-cll-1 chimeric antigen receptors, engineered cells and related methods
WO2024243227A3 (en) Peptides and engineered t cell receptors targeting brachyury antigen and methods of use
WO2024187057A3 (en) Anti-transferrin receptor antibodies and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23824455

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 317580

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 817120

Country of ref document: NZ

Ref document number: AU2023292081

Country of ref document: AU

Ref document number: 2024573283

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2024/015583

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2023292081

Country of ref document: AU

Date of ref document: 20230609

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 202517002310

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2023824455

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 11202408517U

Country of ref document: SG

ENP Entry into the national phase

Ref document number: 2023824455

Country of ref document: EP

Effective date: 20250113

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112024025824

Country of ref document: BR

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23824455

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 202380059379.0

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 202517002310

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 1020257001020

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 202380059379.0

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: MX/A/2024/015583

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 2023824455

Country of ref document: EP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112024025824

Country of ref document: BR

Free format text: APRESENTE O NOVO QUADRO REIVINDICATORIO, CONFORME A PORTARIA/INPI/NO 14/2024, UMA VEZ QUE A APRESENTADA NA PETICAO NO 870240105443 NAO POSSUI A REIVINDICACAO NO 3. A EXIGENCIA DEVE SER RESPONDIDA EM ATE 60 (SESSENTA) DIAS DE SUA PUBLICACAO E DEVE SER REALIZADA POR MEIO DA PETICAO GRU CODIGO DE SERVICO 207.

ENP Entry into the national phase

Ref document number: 112024025824

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20241210